Background: Pyogenic granuloma (PG) is a common, acquired, benign vascular neoplasm of the skin and mucous membranes. It occurs most often in children and adolescents. First-line treatment options for PG are based on destructive approaches. Pain, permanent scarring, and pigmentation are potential complications of these therapies.
Methods: This single-arm, open-label, prospective study evaluated the efficacy of topical propranolol for treatment of PGs in children. All patients clinically diagnosed with cutaneous PG consecutively at the Dermatology Pediatric Outpatient Service of the University of Bologna from January 2010 to December 2010 received a compounded formulation of propranolol ointment 1%.
Results: We found propranolol ointment to be effective in consecutive patients; 59.0% completely regressed in a mean of 66 days, 18.2% remained stable, and 22.7% did not respond. No side effects (eg, skin irritation, allergy, bleeding) were observed.
Conclusion: Topical propranolol ointment 1% with occlusion appears to be an effective treatment for PGs in children. Early treatment was associated with a more favorable outcome.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/pde.13372 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Surgical management of large scalp infantile hemangioma in 30-month-old infant.
Pediatr Med Chir
March 2022
Department of Pediatric Surgery and Pediatric Minimally Invasive Surgery and New Technologies, San Bortolo Hospital, Vicenza.
Infantile Hemangiomas (IH) are the most common benign tumor of infancy, occurring in over 10% of newborns. The head and neck is the most frequently affected area (60%), and the scalp is a typical site for such large lesions. Scalp-IHs are usually focal lesions that can be both disfiguring and may lead to complications such as ulceration and bleeding.
View Article and Find Full Text PDFInfantile hemangiomas (IHs) are the most common vascular abnormalities in children under 1 year old; most IHs involute spontaneously and do not need intervention unless a complication occurs. Ulceration and secondary infection are the most common complications. Despite appropriate conventional wound care, ulcerated IHs are difficult to heal.
View Article and Find Full Text PDFPropranolol regulates ERK1/2 signaling pathway and promotes chronic wound healing in diabetic rats.
Eur Rev Med Pharmacol Sci
May 2019
Department of Endocrinology, Wuwei People's Hospital, Wuwei, P.R. China.
Objective: This study aimed to investigate if propranolol could regulate ERK1/2 signaling pathway and promote chronic wound healing in diabetic rats.
Materials And Methods: Twenty-two rats were used to establish a diabetic chronic wound animal model. They were randomly separated into two groups: the propranolol group and the control group.
The Influence of Formulation and Excipients on Propranolol Skin Permeation and Retention.
Biomed Res Int
November 2018
Food and Drug Department, University of Parma, Parco Area delle Scienze 27/a, 43124 Parma, Italy.
The objective of this work was to study propranolol permeation and skin retention after topical application of different semisolid vehicles, with the final aim of developing new topical formulations intended for the treatment of infantile hemangioma, able to produce therapeutic drug levels in the skin, avoiding systemic absorption. Propranolol ointments, creams, and gels were prepared and tested on pig skin, an accepted model of human skin. From the results obtained in the present work it is clear that the permeation of propranolol across the skin is a poor predictor of its skin retention, at least in the time-frame considered.
View Article and Find Full Text PDFTopical propranolol for infantile haemangiomas: a systematic review.
J Eur Acad Dermatol Venereol
December 2018
ENT Department, University Hospital of Wales, Cardiff, UK.
Infantile haemangiomas are the most common tumour of infancy. Whilst the majority are left untreated to involute spontaneously, residual skin changes commonly occur, particularly in superficial haemangiomas. The current first-line treatment for problematic lesions is oral propranolol; however due to the risk of systemic adverse effects, the use of off-label topical preparations has recently been investigated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!